Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Catherine A.M. Stedman"'
Autor:
Murray L. Barclay, Gary Lim, Thomas Mules, Steven Ding, Jeffrey Ngu, Teresa Chalmers-Watson, Richard B. Gearry, Michael J. Burt, Tyara Banerjee, James D. Falvey, Catherine A.M. Stedman, Bruce A. Chapman
Publikováno v:
GastroHep. 3:5-11
Autor:
Julie Bruneau, Karine Lacombe, Tanya L. Applegate, Margaret Hellard, Adrian Dunlop, Olav Dalgard, Jason Grebely, Jeff Powis, Philip Bruggmann, Gail V. Matthews, Curtis Cooper, Jordan J. Feld, Catherine A.M. Stedman, Brian Conway, Phillip Read, Alberto Moriggia, Alain H. Litwin, Philippa Marks, Christopher S. Fraser, Janaki Amin, Behzad Hajarizadeh, Evan B Cunningham, Gregory J. Dore
Publikováno v:
Clinical Infectious Diseases. 72:1392-1400
Background The aim of this analysis was to calculate the incidence of hepatitis C virus (HCV) reinfection and associated factors among 2 clinical trials of HCV direct-acting antiviral treatment in people with recent injecting drug use or currently re
Publikováno v:
British Journal of Clinical Pharmacology
A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccineAs of 22 June 2021, there have been about 400,000,000 doses of the Pfizer-BioNTech COVID-19 mRNA vaccine administered world-wide. At this time,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::573e5eb8760a1313779099fed9822e35
https://doi.org/10.22541/au.162458630.05700882/v1
https://doi.org/10.22541/au.162458630.05700882/v1
Autor:
David Iser, Catherine A.M. Stedman, L. Stothers, Dennis Petrie, Bridget Draper, William Kemp, Joseph Doyle, Margaret Hellard, Stuart K. Roberts, Paul A. Agius, Alexander J. Thompson, Amanda Wade, Nick Scott, Peter Higgs, Edward Gane, Janine Roney
Publikováno v:
Clinical Infectious Diseases. 70:1900-1906
Background To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to direct-acting antivirals (DAAs), especially among people who inject drugs (PWID). We aimed to determine the effecti
Autor:
Federico J. Mensa, Fred Poordad, Tami Pilot-Matias, Magdy Elkhashab, Neddie Zadeikis, Albert Tran, Carolyn M. Setze, Catherine A.M. Stedman, Ariel Porcalla, Marcus A. Wörns, Yao Yu, Stanley Wang, Joaquin Mario Valdes, S. Greenbloom, T. Nguyen, C.-W. Lin, Jean-Pierre Mulkay, Armen Asatryan, Wei Liu, Edward Gane
Publikováno v:
Clinical infectious diseases, 69 (10
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-f
Autor:
Amanda Erratt, Jordan J. Feld, Curtis Cooper, Gail V. Matthews, Sione Crawford, Adrian Dunlop, David R. Shaw, Catherine A.M. Stedman, Kathy Petoumenos, Tanya L. Applegate, Margaret Hellard, Phillipa Marks, Brian Conway, Erika Castro, Alberto Moriggia, Evan B Cunningham, Jeff Powis, Ian Kronborg, Gregory J. Dore, Patrick Schmid, Edward Gane, Christopher S. Fraser, Julie Bruneau, Olav Dalgard, Jean-Pierre Daulouède, Karine Lacombe, Jason Grebely, Philip Bruggmann, Behzad Hajarizadeh
Publikováno v:
International Journal of Drug Policy. 62:94-103
Background: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir,
Autor:
Matthew W. McClure, Christian Schwabe, Thomas N. Kakuda, Lawrence M. Blatt, John Fry, Edward Gane, Catherine A.M. Stedman, Leen Vijgen, Sushmita Mukherjee Chanda
Publikováno v:
Hepatology. 68:2145-2157
This open-label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct-acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6-12-week oral regimens of 400-800 mg once daily
Autor:
Catherine A.M. Stedman, Tyara Banerjee, Bruce A. Chapman, Gary Lim, Thomas Mules, Richard B. Gearry, Murray L. Barclay, Teresa Chalmers-Watson, Steven Ding, Jeffrey Ngu, Michael J. Burt, James D. Falvey
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efde3a5fba13d68503c680446c317c23
https://doi.org/10.1002/ygh2.436/v2/response1
https://doi.org/10.1002/ygh2.436/v2/response1
Autor:
John McNally, Edward Gane, Giuseppe Morelli, Federico Hinestrosa, K.C. Huang, Gs-Us Investigators, Anu Osinusi, Alexander J. Thompson, Hadas Dvory-Sobol, Kyle Etzkorn, M. Davis, Diana M. Brainard, Mark S. Sulkowski, Mitchell L. Shiffman, John G. McHutchison, Catherine A.M. Stedman
Publikováno v:
Hepatology. 66:1083-1089
The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, w
Autor:
Charlotte Hedskog, Ming Lin, Evguenia S. Svarovskaia, Ronald Nahass, Eric Lawitz, Ziad Younes, Diana M. Brainard, Michael P. Ryan, Catherine A.M. Stedman, John G. McHutchison, Hadas Dvory-Sobol, Hongmei Mo, Edward Gane, Mark S. Sulkowski, Jenny C. Yang, Brian P. Doehle, Sophie Metivier
Publikováno v:
Hepatology Communications
S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic fail